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Transcriptional Analysis of Left-sided Colitis, Pancolitis, and
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Background: It is unknown why patients with extensive ulcerative colitis (UC) have a higher risk of colorectal cancer compared with patients with left-
sided UC. This study characterizes the inﬂammatory processes in left-sided UC, pancolitis, and UC-associated dysplasia at the transcriptional level to
identify potential biomarkers and transcripts of importance for the carcinogenic behavior of chronic inﬂammation.
Methods: The Affymetrix GeneChip Human Genome U133 Plus 2.0 was applied on colonic biopsies from UC patients with left-sided UC, pancolitis,
dysplasia, and controls. Reverse transcription polymerase chain reaction and immunohistochemistry were performed for validating selected transcripts in
the initial cohort and in 2 independent cohorts of patients with UC. Microarray data were analyzed by principal component analysis, and reverse
transcription polymerase chain reaction and immunohistochemistry data by the Wilcoxon’s rank-sum test.
Results: The principal component analysis results revealed separate clusters for left-sided UC, pancolitis, dysplasia, and controls. Close clustering of
dysplastic and pancolitic samples indicated similarities in gene expression. Indeed, 101 and 656 parallel upregulated and downregulated transcripts,
respectively, were identiﬁed in specimens from dysplasia and pancolitis. Validation of selected transcripts hereof identiﬁed insulin receptor alpha
(INSRA) and MAP kinase interacting serine/threonine kinase 2 (MKNK2) with an enhanced expression in dysplasia compared with left-sided UC and
controls, whereas laminin g2 (LAMC2) was found with a lower expression in dysplasia compared with the remaining 3 groups.
Conclusions: This study demonstrates pancolitis and left-sided UC as distinct inﬂammatory processes at the transcriptional level, and identiﬁes
INSRA, MKNK2, and LAMC2 as potential critical transcripts in the inﬂammation-driven preneoplastic process of UC.
(Inﬂamm Bowel Dis 2014;20:2340–2352)
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U lcerative colitis (UC)
1 and Crohn’s disease (CD)2 are the 2
most prevailing chronic inﬂammatory bowel diseases (IBD)
emerging as global diseases with an increasing incidence and
prevalence worldwide.3 UC and colonic CD are associated with
a higher risk of colorectal cancer (CRC),4 and the typical patho-
logical changes progress from quiescent disease to active chronic
inﬂammation without dysplasia to dysplasia, and ultimately
cancer.5 It is assumed that this neoplastic process is inﬂammation
driven,6 which is supported by recent studies7–9 identifying a con-
tinuous inﬂammatory state in the colonic mucosa of patients with
UC, but not in CD, revealing a plausible explanation as to why
the risk of CRC is higher in UC than CD. Hence, the chronic
inﬂammatory load seems to be the central element for an
increased risk of UC-associated CRC.10,11 Furthermore, a range
of epidemiological studies have repeatedly recognized pancolitis
to be an independent risk factor for CRC compared with less
widespread colonic inﬂammation, e.g., left-sided UC.12,13 However,
it is unknown why the inﬂammatory process in pancolitis leads to
a higher risk of CRC compared with left-sided UC. One hypothesis is
that the risk is increased because of an enhanced amount of epithelial
cells in the pancolitic mucosa exposed to carcinogenic insults gener-
ated by the inﬂammation as compared with left-sided UC, a theory in
line with the above-mentioned inﬂammatory load. Alternatively, the
inﬂammation per se may be more “carcinogenic” in the pancolitis
mucosa, and if so, an opportunity exists for the development of more
rational treatment principles for pancolitis. Thus, the question is
whether the inﬂammation of left-sided UC and pancolitis is identical
or of different and gradually more carcinogenic types.
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Therefore, the aim of this study was to use microarray-
based gene expression proﬁling of colonic mucosal biopsies from
controls and patients with UC to characterize the inﬂammatory
processes in left-sided UC, pancolitis, and UC-associated dyspla-
sia and subsequently to identify potential biomarkers and tran-
scripts of importance for the carcinogenic behavior of chronic
inﬂammation.
MATERIALS AND METHODS
Patient Population
Cohort 1, the Microarray Cohort
Colonic mucosal biopsies were from patients from the
Department of Gastroenterology, Medical Section, Herlev Hos-
pital, Denmark or from the Swiss IBD Cohort Study (SIBDCS),
Switzerland. Sixty patients were enrolled: 6 patients with UC with
dysplasia, 19 patients with UC with pancolitis, and 20 UC patients
with left-sided colitis, as well as 15 controls, i.e., patients
undergoing colonoscopy and where all investigations subse-
quently turned out to be normal (Table 1).
Cohort 2, the Polymerase Chain Reaction Cohort
Colonic mucosal biopsies were from patients, subjected to
ﬂexible colonoscopy at the Department of Gastroenterology,
Medical Section, Herlev Hospital, Denmark. Forty patients were
enrolled: 23 UC patients with left-sided colitis and 17 patients
with UC with pancolitis (Table 1).
Cohort 3, the Polymerase Chain Reaction and
Immunohistochemistry Cohort
The third cohort was established through inclusion of
formalin ﬁxed parafﬁn embedded (FFPE) colonic biopsies
originating from the Department of Pathology, Herlev Hospital,
Denmark. Six patients with UC with dysplasia, 4 patients with
UC with pancolitis, and 4 UC patients with left-sided UC were
included (Table 1).
All eligible patients with UC had their diagnosis veriﬁed by
established criteria,14 and when biopsies were obtained, they were
graded in accordance with the Mayo score.15 The endoscopic
assessment of activity was conﬁrmed by a histological examina-
tion, and any discrepancy between the observations led to exclu-
sion of the speciﬁc patient. The included controls had no signs of
inﬂammation. Exclusion criteria were age above 80 or below 18
years, clinical evidence of infection, recent (within 14 d) intake of
antibiotics or probiotics, pregnancy, or severe mental illness.
Ethical Considerations
The Swiss Ethics Committees approved the SIBDCS, and
the Scientiﬁc Ethics Committee of the Copenhagen Region
(H-KA-20060164) approved the study as well. All patients
participated in this study in conﬁrmation with the principals
outlined in the Declaration of Helsinki. Informed written consent
was obtained from each participating person.
Tissue Samples
Cohorts 1 and 2
Mucosal colonic biopsies (10–20 mg each) were obtained
endoscopically using routine endoscopic forceps. The descending
colon was explicitly chosen to avoid any intersegmental variation
in gene expression and because this is the most frequent area of
inﬂammation. The biopsies originated from an inﬂamed area
(aside from the control group and 3 of the 6 dysplastic samples)
without ulceration. The ﬁrst biopsy was used for a histopatholog-
ical evaluation conducted in an unblinded fashion by staff pathol-
ogists in accordance with well-established criteria and focused on
conﬁrming the presence or absence of inﬂammation.16 The second
biopsy was immediately stabilized in RNAlater (Ambion, Austin,
TX) to minimize RNA degradation, and after 48 hours of storage
in RNAlater at 48C, the biopsy was kept at 2808C.
All dysplastic samples (cohort 1) also originated from the
left side of the colon and contained low-grade dysplasia except for
one sample containing high-grade dysplasia.
Cohort 3
FFPE biopsies from the descending colon of UC patients
with left-sided UC, pancolitis, and dysplasia were randomly
chosen from the biobank at the Department of Pathology, Herlev
Hospital, Denmark. Just as in cohorts 1 and 2, the biopsies
originated from an inﬂamed area without ulceration, which was
conﬁrmed in a blinded fashion by staff pathologists. Four of the
dysplastic samples contained low-grade dysplasia, whereas 2
contained high-grade dysplasia (Table 1).
RNA Extraction, Hybridization, Detection, and
Quantiﬁcation of Signals
RNA was extracted from biopsies in RNAlater with
the NucleoSpin RNA/Protein mini kit (Macherey-Nagel, Düren,
Germany) and from FFPE biopsies with Rneasy FFPE Kit
(Qiagen, Hilden, Germany) in accordance with the manufactures
protocols. Integrity and purity were veriﬁed with an Agilent
Bioanalyzer (Palo Alto, CA).
In accordance with the Affymetrix protocol and the one-cycle
eukaryotic target labeling assay, biotin-labeled complementary RNA
was produced. The complementary RNA was fragmented, and
a hybridization mix was prepared, which included the fragmented
target, probe array controls, bovine serum albumin, and herring
sperm DNA. In this experiment, the Affymetrix GeneChip Human
Genome U133 Plus 2.0 was applied (.47.000 transcripts). The
hybridized probe array was subsequently stained with ﬂuorescent
protein streptavidin–phycoerythrin17 and scanned with a GeneArray
scanner at the excitation wavelength of 488 nm. The amount of light
emitted at 570 nm was proportional to the bound target at each
location on the probe array. Data were stored as image ﬁles for
further analysis. These procedures were all performed at the Micro-
array Core Facility, Rigshospitalet, Copenhagen, Denmark. The sam-
ples were run as 2 batches containing a mixture of sample types, i.e.,
pancolitis, left-sided UC, dysplasia, and controls, facilitating
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a subsequent identiﬁcation of a potential batch effect with the
principal component analysis (PCA). All data from this study
have been submitted to the Gene Expression Omnibus (NCBI/
GEO: Series GSE47908), http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?token¼rdcrfuummasqyrc&acc¼GSE47908.
Real-time Reverse Transcription Polymerase
Chain Reaction
Primers for ampliﬁcation were chosen from the PrimerBank
resource. All ampliﬁed polymerase chain reaction (PCR) products
were sequenced to verify the expected identity, and melting
curves were routinely checked to rule out the ampliﬁcation of
unrelated fragments during quantitative real-time reverse tran-
scription polymerase chain reaction (RT-PCR). A 100 ng of
reverse-transcribed total RNA was used as template. The PCR
reactions were run using the LightCycler PCR system (Roche,
Manheim, Germany) as previously described.18 To standardize the
reactions, a serial 10-fold dilution of gel-puriﬁed PCR product of
1 mL was used as template in independent reactions, and the
number of target molecules was calculated based on the standard
curve. The number of ribosomal protein L10 transcripts (RPL10)
was used for normalization between samples, as RPL10 was
found constitutively and equally expressed in the microarray data
from the 4 groups (calculated for probe set ID: “221989_at.”
analysis of variance, P ¼ 0.99) and thus a suitable positive
PCR control. The ampliﬁcation efﬁcacy was calculated from the
slope of the standard curve for each primer pair. The average
ampliﬁcation efﬁciency for the primer pairs was 86% (range,
75%–99%) for cohort 1, 88% (range, 76%–99%) for cohort 2,
and 82% (range, 76%–99%) for cohort 3.
Immunohistochemistry
Four-micrometer sections of FFPE tissue were pretreated
by deparafﬁnization, rehydration, and epitope retrieval in 1 step
TABLE 1. Clinical Details
Dysplasia Pancolitis Left-sided UC Controls P
Cohort 1 (microarray)
n 6 19 20 15
Gender (male/female) 4/2 9/10 7/13 4/11 0.32
Age, median (IQR), yr 49 (28) 32 (22) 42 (30) 52 (34) 0.16
Years with disease (,10 yr/.10 yr) 2/4 13/6 13/7 — 0.29
Mayo score, median (IQR) 1.5 (5) 6 (5) 6 (4) — 0.07
Mayo endoscopic score, median (IQR) 0.5 (2) 2 (1) 2 (0) — 0.09
Smoking/nonsmoking 0/6 0/19 3/17 2/13 0.27
Daily medicationa 2/0/0/0/2/0/2 15/5/6/2/8/5/0 17/3/3/2/5/1/2 — 0.09
Cohort 2 (RT-PCR)
n — 17 23 —
Gender (male/female) — 6/11 10/13 — 0.82
Age, median (IQR), yr — 32 (17) 40 (17) — 0.03
Years with disease (,10 yr/.10 yr) — 12/5 16/7 — 1.0
Mayo score, median (IQR) — 11 (4) 6 (2) — 0.0001
Mayo endoscopic score, median (IQR) — 2 (1) 1 (1) — 0.0001
Smoking/nonsmoking — 3/14 0/23 — 0.09
Daily medicationa — 15/8/5/1/5/2/2 18/15/5/1/5/1/2 — 0.93
Cohort 3 (RT-PCR and IHC)
n 6 4 4 —
Gender (male/female) 3/3 3/1 3/1 — 0.62
Age, median (IQR), yr 61 (37) 51 (18) 47 (35) — 0.57
Years with disease (,10 yr/.10 yr) 1/5 4/0 3/1 — 0.02
Mayo score, median (IQR) 4 (5) 6.5 (2) 6 (5) — 0.42
Mayo endoscopic score, median (IQR) 1 (2) 2 (1) 1.5 (1) — 0.30
Smoking/nonsmoking 0/6 0/4 0/4 — na
Daily medicationa 4/1/0/0/2/0/1 2/1/0/0/0/0/2 2/1/1/0/1/0/1 — 0.77
Biopsies from cohorts 1 and 2 are fresh Later-conserved biopsies, whereas biopsies from cohort 3 are FFPE biopsies.
aSystemic 5-ASA/topical 5-ASA/systemic steroids/topical steroids/thiopurines/inﬂiximab/none.
IQR, interquartile range.
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by use of “Pretreatment Module” (PT-Link; Dako, Glostrup,
Denmark) according to manufacturer’s instruction. Immunohisto-
chemistry (IHC) staining was performed using the “Dako Autostainer
Link” and with the commercially available kit (EnVision Flex; Dako).
Slides were counterstained with Mayer’s hematoxylin before viewing.
The antibodies were MAP kinase-interacting serine/threonine-protein
kinase 2 (MKNK2, ab84345, dilution 1:500; Abcam), thyroid
hormone receptor alpha 1 (THRA, ab53729, dilution 1:50; Abcam,
Cambridge, MA), insulin receptor alpha (INSRA, I7661–25E, dilution
1:50; US Biological, Salem, MA), laminin gamma 2 (LAMC2, M
7262, dilution 1:50; Dako), integrin alpha 6 (ITGA6, HPA012696-
100UL, dilution 1:50; Sigma–Aldrich, Brøndby, Denmark), and ezrin
(EZR, sc-58758, dilution 1:50; Santa Cruz Biotechnology, Heidelberg,
Germany). Spleen tissue was used as a positive control for MKNK2,
and colon carcinoma tissue was used as positive control for THRA,
LAMC2, ITGA6, and EZR. Placental tissue was used as a positive
control for INSRA. Evaluation of the stained slides was performed by
quantitative scoring of the intensity and fraction of cells stained. The
immunoreactivity was graded from 0 to 3 according to intensity: 0 if
the staining was absent, 1 for weak staining, 2 for moderate staining,
and 3 for intense staining. The intensity scoring and evaluation of
fraction of stained cells was performed blinded by an IBD pathologist.
Data Analysis
The clinical data (Table 1) were compared by the x2 test
(categorical variables) or Kruskal–Wallis (continuous variables)
with GraphPad Prism v.6.0 (GraphPad Software, La Jolla, CA).
P-values ,0.05 were considered signiﬁcant.
Potential covariates in the clinical data (i.e., age, Mayo
score, current medication, and years with disease) were accounted
for with the use of partial least squares regression-discriminant
analysis in SIMCA-P + 12 (Umetrics, Umeå, Sweden); micro-
array data as an X matrix and the potential covariates as the Y
variables.19
By performing the robust multiarray analysis procedure20
with quantile normalization implemented in the Affymetrix
library for the R statistical environment,21 a single log2 scale
expression measure for each probe set was attained from the
low-level data ﬁles (CEL ﬁles).
The unsupervised multivariate data analysis tool PCA22 was
used to determine whether any intrinsic clustering existed within
the data set and to identify any obvious batch effects. This was
performed with the R package pcaGoPromoter,23 which provides
an overview of the data by PCA and at the same time produces
a functional interpretation by gene ontology (GO) terms (biologi-
cal processes). The GO terms were included only if P , 0.005. In
short, if different groups of samples are clearly separated along
a principal component axis, the pcaGoPromoter algorithm will
identify the transcripts holding the strongest differential power
and subject the identiﬁed transcripts to an overrepresentation anal-
ysis, e.g., a Fisher’s exact test.
The Hotelling’s T2 test was conducted on the 2-component
PCA model. In brief, the scores for each sample were applied to
a multiple linear regression model using a dummy variable to
encode the classes (left-sided UC, pancolitis, and dysplasia,
respectively). The calculations were performed in R. Dysplasia
was tested against pancolitis and left-sided UC, respectively.
To determine whether the inﬂammation per se may be more
carcinogenic in the pancolitis mucosa compared with left-sided
UC, corresponding deregulated transcripts had to be identiﬁed in
both pancolitis and dysplasia when compared with left-sided UC
and controls. Thus, to extract a list of genes with higher
expression values in dysplasia and pancolitis as compared with
left-sided UC, several ﬁlters were applied: (1) The false discovery
rate corrected P-value of a t test (the expression data are on a log2
scale, and a parametric test was accordingly used) comparing the
mean expression in dysplasia with left-sided UC should be
,0.0001, and the fold differences 2-fold or greater in dysplasia,
arbitrary values. (2) The mean difference in expression values
between dysplasia and pancolitis should be less than 1.3 (on
a normal scale). This ﬁlter assures that the upregulated transcripts
found in dysplasia versus left-sided UC are also upregulated in
pancolitis. (3) The mean difference in expression values between
left-sided UC and controls should be less than 1.3 (on a normal
scale). This ﬁlter eliminates transcripts that just reﬂect inﬂamma-
tion per se.
To extract a list of transcripts with lower expression in
dysplasia compared with left-sided UC the following ﬁlter was
applied: The false discovery rate corrected P-value of a t test
comparing the mean expression in dysplasia with the mean
expression in left-sided UC should be ,0.0001, and the mean
expression in left-sided UC should be more than 2.5-fold higher
(on a normal scale) than the mean expression level in dysplasia.
The RT-PCR data and IHC data were analyzed with the
Wilcoxon’s rank-sum test, and the results were considered signif-
icant when P , 0.05.
RESULTS
Array Analysis Reveals Separate Clusters of
Gene Expression for Left-sided UC and Colitis,
Pancolitis, Dysplasia, and Controls
An initial PCA score plot containing all 4 sample types, i.e.,
left-sided UC, pancolitis, dysplasia, and controls, was performed
to make sure that the diseased samples clustered away from the
control samples and to detect any potential batch effect. As seen
in Figure 1A, there is a separate clustering of all 4 groups, which
means that the gene expression proﬁles of the diseased samples
are distinct from each other and the control samples. The cluster-
ing of the 4 groups also implies that the batch effect is at an
absolute minimum as the samples were run in 2 batches with
a mixture of sample types. To get insight into the biological pro-
cesses involved and to identify differentially expressed tran-
scripts, a subsequent PCA model was constructed containing
only diseased samples. This PCA score plot (Fig. 1B) illustrates
a 3-way separation of the samples in accordance with class be-
longings: left-sided UC, pancolitis, and dysplasia, respectively.
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FIGURE 1. PCA score plots of the microarray data. A, The PCA score plot is described by 2 principal components (PC1 and PC2) containing 31% of
the variance and illustrates separate clustering of the 4 sample types with only very few samples overlapping. These samples have been
re-evaluated without any changes in their diagnosis. B, The PCA score plot illustrates a 3-way separation of the samples in accordance with class
belonging. The separation is primarily along PC1 containing 18% of the variance: samples from patients with left-sided UC are localized toward
positive values, samples from patients with dysplasia toward negative values, and samples from patients with pancolitis in the middle. Each axis in
both PCA score plots is functionally annotated with the 5 most signiﬁcant (P , 0.005) Gene ontology terms. BP, biological processes.
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The PCA model is described by 2 components explaining a total
of 31% (R2X) of the variation in the dataset. Most of the variance
is observed along the ﬁrst principal component (PC1, R2X ¼
18%) with samples from patients with left-sided UC located
toward positive values, dysplasia toward negative values, and
pancolitis in the middle. The Hotelling’s T2 test was conducted
on the PCA model and conﬁrmed signiﬁcant differences of the
gene expression signatures: dysplasia versus pancolitis, P , 0.01;
dysplasia versus left-sided UC, P , 10213; and pancolitis versus
left-sided UC, P , 1029.
To test whether potential covariates could have a signiﬁcant
effect on these results, individual partial least squares regression-
discriminant analysis models were constructed for age, years with
disease, Mayo score, Mayo endoscopic score, and medication, as
these were either signiﬁcantly different between the groups or
a trend was observed (Table 1). However, none of these models
turned out to be predictive (data not shown).
Identiﬁcation of Transcripts Relevant
for Clustering
The top 5 GO terms that relate to the gene expression
proﬁles of left-sided UC are described by processes such as pro-
tein metabolic process and cell cycle process, whereas the GO
terms that represent dysplasia and pancolitis relate to biological
processes such as cellular response to insulin and response to
insulin stimulus (Fig. 1B).
To identify the gene expression proﬁle responsible for the
differentiation between pancolitis and left-sided UC and to simul-
taneously identify potential biomarkers or transcripts of signiﬁcant
importance in the inﬂammation-driven preneoplastic process, the
statistical ﬁlters described in Materials and Methods were applied.
The resulting lists of deregulated transcripts are given in Tables,
Supplemental Digital Content 1 and 2, http://links.lww.com/IBD/
A625 and http://links.lww.com/IBD/A626, respectively. Table, Sup-
plemental Digital Content 1, http://links.lww.com/IBD/A625 con-
tains 101 transcripts signiﬁcantly upregulated in both pancolitis
and dysplasia compared with left-sided UC and controls, whereas
Table, Supplemental Digital Content 2, http://links.lww.com/IBD/
A626 represents 656 signiﬁcantly downregulated transcripts in pan-
colitis and dysplasia compared with left-sided UC and controls.
Validation of Relevant Transcripts by RT-PCR
and IHC
A panel of selected transcripts from these lists was
internally validated by RT-PCR on all samples from cohort 1
(the microarray cohort, i.e., 6 dysplasia, 19 pancolitis, 20 left-sided
UC, and 15 controls; Table 1). As it is extremely difﬁcult to get
hold of fresh–frozen or RNAlater-conserved biopsies with
UC-associated dysplastic material, the external validation of the
selected transcripts was performed on 2 different external cohorts:
cohort 2 (the PCR cohort, i.e., fresh samples from 23 left-sided UC
and 17 pancolitis; Table 1) to focus on potential differences
between pancolitis and left-sided UC and cohort 3 (the PCR and
IHC cohort, i.e., FFPE biopsies from 4 pancolitis, 4 left-sided UC,
and 6 dysplasia; Table 1) to focus on potential differences between
dysplasia, pancolitis, and left-sided UC and evaluate the potential
signiﬁcance of FFPE biopsies as validation material.
The selection of transcripts from these lists was based on
their known involvement in inﬂammatory and neoplastic processes,
and they had to be related to 1 or more of the biological processes
described in the PCA score plots. RT-PCR was consequently
performed in cohort 1 on insulin receptor alpha (INSRA), thyroid
hormone receptor alpha 1 (THRA), MAP kinase-interacting serine/
threonine-protein kinase 2 (MKNK2), laminin gamma 2 (LAMC2),
integrin alpha 6 (ITGA6), ezrin (EZR), epidermal growth factor
receptor (EGFR), signal transducer and activator of transcription 1
(STAT1), integrin b6 (ITGB6), cathepsin Z (CTSZ), hepatocyte
nuclear factor 4g (HNF4G), apoptosis inhibitor 5 (API5), eukary-
otic translation initiation factor 4A2 (EIF4A2), Sp3 transcription
factor (SP3), myosin 1C (MYO1C), and laminin beta 1 (LAMB1).
Transcripts without different expression levels in dysplasia and
controls or within the diseased patient groups, i.e., dysplasia,
pancolitis, and left-sided UC were excluded for further analysis
(see Fig., Supplemental Digital Content 3, http://links.lww.com/
IBD/A627), as the objective of this study was to identify poten-
tial biomarkers and transcripts of importance for the carcino-
genic behavior of chronic inﬂammation. The RT-PCR results
for which differences were observed are illustrated in Figures
2A and 3A. An overall higher expression of INSRA, THRA, and
MKNK2 was seen in the diseased sample types (i.e., left-sided
UC, pancolitis, and dysplasia) compared with controls (except
for INSRA in left-sided UC). Furthermore, mimicking the
microarray data, INSRA, THRA, and MKNK2 transcripts were
found in higher abundance in dysplasia compared with left-sided
UC (Fig. 2A). Similarly, a lower expression of LAMC2, ITGA6,
and EZR was found in dysplasia compared with controls and
inﬂamed tissue (except for EZR in pancolitis; Fig. 3A). These 6
transcripts were further sought validated in external validation
cohorts.
Thus, focusing on the differences between pancolitis and
left-sided UC cohort 2 demonstrated a signiﬁcant difference in the
expression of INSRA, whereas only a trend was observed for
MKNK2, and no difference was seen for THRA (Fig. 2B).
Similarly, ITGA6 was found with a higher expression in panco-
litis compared with left-sided UC, and trends were seen for
LAMC2 and EZR (Fig. 3B).
In cohort 3, the expression of INSRA was signiﬁcantly
higher in dysplasia compared with left-sided UC, which was also
true for MKNK2, where a signiﬁcant difference was also seen
between pancolitis and left-sided UC (Fig. 2C). Again, no differ-
ences were observed for THRA, although a clear trend was seen
with higher expression in dysplasia compared with left-sided UC.
Finally, no differences between the 3 groups could be identiﬁed in
relation to LAMC2, ITGA6, and EZR, although P-values of 0.05
were seen with LAMC2 and ITGA6 when comparing pancolitis
and left-sided UC (Fig. 3C).
To investigate whether the deregulated transcripts (i.e.,
MKNK2, THRA, INSRA, LAMC2, ITGA6, and EZR) translate
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into changed protein levels, IHC staining was performed on FFPE
biopsies from all patients in cohort 3. As seen in Figures 4 and 5,
a signiﬁcantly increased intensity score was observed for INSR in
dysplasia when compared with both pancolitis and left-sided UC,
whereas the score was signiﬁcantly lower for LAMC2 in dyspla-
sia compared with both pancolitis and left-sided UC. No differ-
ences in the intensity scores could be documented for the
remaining transcripts. Control hematoxylin and eosin of normal
colonic mucosa, left-sided UC, pancolitis, and colonic mucosa
with UC-associated dysplasia are presented in Fig., Supplemental
Digital Content 4, http://links.lww.com/IBD/A628.
DISCUSSION
With the intention to characterize the inﬂammatory pro-
cesses at the transcriptional level in left-sided UC, pancolitis, and
UC-associated dysplasia, this study used gene expression pro-
ﬁling of colonic mucosal biopsies. To the best of our knowledge,
a similar approach has never previously been published, which
makes the identiﬁcation of pancolitis and left-sided UC as distinct
inﬂammatory processes at the transcriptional level a novel ﬁnding
(Fig. 1).
The transcriptional analysis also revealed that the gene
expression proﬁle of UC-associated dysplasia was distinct from
both pancolitis and left-sided UC. However, the proximity of
dysplastic and pancolitic samples in the PCA score plot (Fig. 1B)
indicated similarities in the gene expression proﬁle, and as the
objective of this study was to identify transcripts of importance
for the carcinogenic behavior of pancolitis, similarities between
dysplasia and pancolitis were the main focus of the succeeding
analyses. Thus, 101 and 656 parallel upregulated and downregu-
lated transcripts, respectively, were subsequently identiﬁed in
FIGURE 2. Real-time RT-PCR quantiﬁcation of selected upregulated gene expressions. Transcripts for the insulin receptor alpha (INSRA), thyreoid
hormone receptor alpha 1 (THRA), and MAP kinase-interacting serine/threonine–protein kinase 2 (MKNK2) were measured in RNA extracted from
(A) all of the samples in the initial microarray cohort 1, (B) the external validation cohort 2, and (C) external validation cohort 3. The number of
ribosomal protein L10 (RPL10) transcripts was used for normalization between samples. The box border represents the interquartile range, and the
horizontal line in the box is the median. The whiskers show the largest/smallest observation falling within a distance of 1.5 times the box size. *P,
0.05, **P , 0.01, ***P , 0.001, ****P , 0.0001. The P-values are not corrected for false discovery rates.
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dysplasia and pancolitis (see Tables, Supplemental Digital
Content 1 and 2, http://links.lww.com/IBD/A625 and http://
links.lww.com/IBD/A626).
From the upregulated list (see Table, Supplemental Digital
Content 1, http://links.lww.com/IBD/A625), the RT-PCR vali-
dated transcripts of MKNK2, THRA, and INSRA showed an
overall higher expression in diseased samples as compared with
controls, and a signiﬁcant difference was found between dysplasia
and left-sided UC, which was not the case for pancolitis (cohort 1;
Fig. 2A). These results were partially validated in cohorts 2 and 3,
especially regarding INSRA and MKNK2, which were found
highly expressed in dysplastic tissue as compared with left-
sided UC, and MKNK2 was also found with a higher expression
in pancolitis as compared with left-sided UC (cohorts 2 and 3;
Fig. 2B, C).
The 3 transcripts, i.e., INSRA, THRA, and MKNK2 are
part of the same intracellular signaling pathways: the
phosphatidylinositide 3-kinase (PI3K) and mitogen-activated
protein kinase (MAPK) signaling pathways (Fig. 6), which are
key cellular transduction pathways in normal functional cells and
important regulators of cellular growth, metabolism, and survival.
Recent evidence, however, recognizes INSRA and THRA as
being overexpressed in several tumors including colonic adeno-
mas24 and CRC.25 The PI3K and MAPK signaling pathways con-
verge on MKNK2, as does several pathways of a range of
inﬂammation-associated cytokine receptors (e.g., interleukin 1
and tumor necrosis factor alpha; Fig. 6). Activated MKNK2 and
MKNK1 (MKNKs) phosphorylate eukaryotic initiation factor 4E
(eIF4E), which is the rate-limiting step in the activation of the
eIF4G complex that directs protein biosynthesis. Thus, by inhib-
iting MKNKs, studies have demonstrated a signiﬁcant reduction
in the release of proinﬂammatory cytokines, such as tumor necro-
sis factor alpha, interleukin 1b, and interleukin 6 in activated T
cells and keratinocytes.26,27 Furthermore, several lines of evidence
FIGURE 3. Real-time RT-PCR quantiﬁcation of selected downregulated gene expressions. Transcripts for laminin gamma 2 (LAMC2), integrin alpha 6
(ITGA6), and ezrin (EZR) were measured in RNA extracted from (A) all of the samples in the initial microarray cohort 1, (B) the external validation
cohort 2, and (C) external validation cohort 3. The number of ribosomal protein L10 (RPL10) transcripts was used for normalization between
samples. The box border represents the interquartile range, and the horizontal line in the box is the median. The whiskers show the largest/smallest
observation falling within a distance of 1.5 times the box size. *P , 0.05, **P , 0.01. The P-values are not corrected for false discovery rates.
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FIGURE 4. Immunohistochemical staining of INSR, THRA, and MKNK2. A, Representative immunohistochemical staining of INSRA, THRA, and
MKNK2 in FFPE colonic biopsies from a patient with dysplasia, pancolitis, or left-sided UC. The samples are counterstained with hematoxylin.
Original magniﬁcation ·400. INSRA is presented with a ·40 lens to visualize the membrane staining, whereas THRA and MKNK2 are presented with
a ·20 lens. Thus, INSRA is expressed in the cytoplasm and along the basolateral membranes of the colonocytes, the THRA is expressed in the
cytoplasm and nucleus, and MKNK2 is expressed primarily in the cytoplasm of colonocytes. B, Scatter plot of the intensity scores (0 ¼ negative
stain, 1 ¼ mild stain, 2 ¼ moderate stain, and 3 ¼ strong stain) and fraction of stained cells for all 14 patients in cohort 3. The vertical lines
represent the median scores. **P , 0.01. The P-values are not corrected for false discovery rates.
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FIGURE 5. Immunohistochemical staining of LAMC2, ITGA6, and EZR. A, Representative immunohistochemical staining of LAMC2, ITGA6, and EZR
in FFPE colonic biopsies from a patient with dysplasia, pancolitis, or left-sided UC. The samples are counterstained with hematoxylin. Original
magniﬁcation ·400. LAMC2 is presented with a ·20 lens, whereas ITGA6 and EZR are presented with a ·40 lens to visualize the membrane
staining. Thus, LAMC2 is primarily expressed in the cytoplasm of colonocytes, but in regions with invasive appearances in the dysplastic tissue, the
expression becomes more membranous. ITGA6 is expressed in the basolateral membrane of colonocytes and becomes more intense in regions
with invasive characteristics in the dysplastic tissue. EZR is found primarily in the apical membrane of colonocytes but is also seen associated with
the cytoskeleton. B, Scatter plot of the intensity scores (0 ¼ negative stain, 1 ¼mild stain, 2 ¼moderate stain, and 3 ¼ strong stain) and fraction of
stained cells for all 14 patients in cohort 3. The vertical lines represent the median scores. *P , 0.05, **P, 0.01. The P-values are not corrected for
false discovery rates.
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indicate that overexpressed and phosphorylated eIF4E serves as
a genuine oncogenic accelerator in a milieu of cancer, which
seems to play an important role in the early stages of malignant
transformation as compared with the late stages of CRC.28–30
More importantly, a recent study conﬁrmed that phosphorylation
of eIF4E by MKNKs is essential for the ability of eIF4E to
promote tumorigenesis,31 whereas it is dispensable for growth
and development in normal tissue.32 Taken together, these obser-
vations make MKNKs ideal and novel targets in cancer therapy
and in the treatment of IBD, and they may ultimately serve as
a new therapeutic chemopreventive avenue in the treatment of
especially pancolitis with potentially very few side effects.
From the downregulated list (see Table, Supplemental
Digital Content 2, http://links.lww.com/IBD/A626), the RT-PCR
validated transcripts of LAMC2, ITGA6, and EZR: showed a sig-
niﬁcant lower expression in dysplasia as compared with controls
(cohort 1; Fig. 3) and inﬂamed samples (except for dysplasia
versus pancolitis). No differences between inﬂamed samples were
documented in cohort 1 (Fig. 3A), but external validation identi-
ﬁed ITGA6 being signiﬁcantly higher expressed in pancolitis
compared with left-sided UC (cohort 2; Fig. 3B), and similar
trends were observed for LAMC2 and EZR. Nevertheless, the
proteins of all 3 transcripts are essential for the integrity and
homeostasis of the epithelial barrier, as they are vital components
FIGURE 6. Schematic representation of the intracellular signaling pathways in which INSRA, THRA, and MKNK2 are pivotal elements. Ligand
binding to INSRA stimulates the tyrosine kinase activity of the receptor, which phosphorylates several substrates including IRS1/2 (insulin receptor
substrate 1/2) and Shc/Grb2/Sos (adaptor protein Src homology 2 domain-containing/shc/growth factor receptor bound protein-2/Son of Sev-
enless protein) complexes. IRS proteins and the ligand bound THRA are able to interact with the regulatory subunit (p85) of PI3K (phosphati-
dylinositide 3-kinase) resulting in an activation of the catalytic subunit (p110) and subsequently activation of AKT and mammalian target of
Rapamycin (mTOR). Activated mTOR liberates eIF4E (eukaryotic initiation factor 4E) from the inhibitory binding protein 4EBP1 (eIF4E-binding
protein 1), and eIF4E is free to engage the scaffolding protein eIF4G and be phosphorylated by MKNKs, which is the rate-limiting step in the
activation of the eIF4F translation initiating complex (eIF4G, eIF4E, and eIF4A). The activated Shc/Grb2/Sos complex along with ligand bound
cytokine receptors trigger the MAPK (mitogen-activated protein kinases) pathways of ERK (extracellular signal–regulated kinase) and p38, which
activate MKNKs promoting protein synthesis, mitogenesis, and oncogenesis.
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of various types of junctions (e.g., tight junctions, adherent junc-
tions, and desmosomes) necessary for fundamental intercellular
adhesion and cell–matrix interaction.33–35 In addition to their role
in stable adhesion, these proteins are also important in cell migra-
tion and have consequently been found upregulated during wound
healing and tumorigenesis.35–37
The lower LAMC2, ITGA6, and EZR gene expressions in
UC-associated dysplasia as described in cohort 1 have, to our
knowledge, not been described previously. As they persistently
have been found upregulated in CRC, the decreased expression
seems to distinguish this premalignant state from both normal,
inﬂamed, and cancerous tissue in the colon.38–41 Thus, especially
LAMC2 may constitute a potential biomarker of preneoplastic
lesions in patients with UC. However, the downregulation of
LAMC2, ITGA6, and EZR seen in cohort 1 was not validated
in cohort 3, which signiﬁes one of the weaknesses in this study;
cohort 3 was based on a relative low number of patients and
FFPE biopsies, and the results have to be interpreted with this
matter in mind. However, despite the expected low RNA integrity
number values (average RNA integrity number value 2.1) accept-
able ampliﬁcation efﬁciencies (average 82%; range, 76%–99%)
were achieved making the RT-PCR results valid and consequently
illustrates the feasibility of using FFPE biopsies as a valuable
source for retrospective gene expression studies in the future.
The ﬁndings at the transcriptional level concurred with the
IHC results for INSRA and LAMC2. The INSRA demonstrated
a signiﬁcantly higher intensity score in dysplasia compared with
inﬂamed samples (Fig. 4B), and LAMC2 a signiﬁcantly lower
intensity score in dysplasia compared with inﬂamed samples,
whereas the fraction of stained cells was signiﬁcantly higher
in dysplasia and pancolitis as compared with left-sided UC
(Fig. 5B). IHC did not indicate signiﬁcant differences for expres-
sion of THRA, MKNK2, ITGA6, and EZR. If subtle differences
are present at the protein level as indicated by the transcriptional
data, more sensitive protein analyses are needed, which unfortu-
nately was not an option in the current experimental setting.
Further potential limitations of this study include the partial dis-
crepancy between the microarray and PCR results, a discrepancy,
i.e., explained by the 30 end based microarray. Correlation coef-
ﬁcients between these 2 technologies have been found to be as
low as 0.4,42 but a possible solution to circumvent this problem in
future studies would be the combination of microarray and cap
analysis gene expression.43 A higher number of dysplastic sam-
ples clearly would have been preferable, although exact power
calculations are impossible without preliminary data at hand.
Finally, a range of possible covariates was accounted for, but
the potential confounding effect of these factors needs to be taken
into consideration when interpreting the results.
In conclusion, with the use of gene expression proﬁles of
mucosal biopsies, this study recognizes pancolitis and left-
sided UC as distinct inﬂammatory processes at the transcrip-
tional level and identiﬁes transcripts of potential importance for
the carcinogenic behavior of pancolitis. INSRA and MKNK2
seem to be key mediators of inﬂammation and tumorigenesis,
and especially MKNK2 presents itself as a possible new
therapeutic chemopreventive avenue in the treatment of pan-
colitis. LAMC2 seems to constitute an ideal biomarker of
preneoplastic lesions in patients with UC, although this remains
to be validated. Finally, it has been demonstrated that FFPE
biopsies are valid and a valuable source for retrospective gene
expression studies.
Future studies at the transcription level will have to include
inﬂammatory controls and non-IBD patients with CRC. At the
functional level, studies will need to focus on 1 or a few of the
identiﬁed transcripts linking pancolitis and UC-associated dyspla-
sia, and thus evaluate whether manipulation with the expression
levels will have any signiﬁcant inﬂuence on experimental models
of colitis and colitis-associated colon cancer carcinogenesis.
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